Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy

BACKGROUND: The combination of docetaxel chemotherapy and androgen deprivation therapy (ADT) has become a standard treatment for patients with metastatic prostate cancer. The recently accrued Phase III CALGB 90203 trial was designed to investigate the clinical effectiveness of this treatment approac...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Beltran, Himisha, Wyatt, Alexander W, Chedgy, Edmund C, Donoghue, Adam, Annala, Matti, Warner, Evan W, Beja, Kevin, Sigouros, Michael, Mo, Fan, Fazli, Ladan, Collins, Colin C, Eastham, James, Morris, Michael, Taplin, Mary-Ellen, Sboner, Andrea, Halabi, Susan, Gleave, Martin E
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5690882/
https://ncbi.nlm.nih.gov/pubmed/28842510
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1034
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi